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Editorial  Parkinson’s Disease
The Future of Parkinson’s Treatment – 
Personalised and Precision Medicine
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1. Federal State Budgetary Educational Institution of Higher Education ‘N.I. Pirogov Russian National Research Medical University’ of the Ministry of 
Healthcare of the Russian Federation, Moscow, Russia; 2. Neurodegenerative Diseases Research Group, Institute of Pharmaceutical Science, Faculty 
of Life Sciences and Medicine, King’s College London, UK; 3. National Parkinson Foundation International Centre of Excellence, King’s College 
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T he modern concept of Parkinson’s disease (PD) has changed and evolved and we consider Parkinson’s to be a multi-neurotransmitter dysfunction-related disorder with central and peripheral nervous system involvement. The clinical expression is thus a mixture of the outwardly evident motor symptoms and a range of ‘hidden’ non-motor symptoms. The complex underlying neuropathology of PD calls 
for a reassessment of the treatment strategies currently used. Treatment of PD is guideline-driven and in most cases based on a dopamine 
replacement strategy or surgical manipulation of brain dopaminergic pathways. Treatment of many non-dopaminergic non-motor and some 
motor symptoms, which have major effects on quality of life, continue to remain a key unmet need. Like in other chronic conditions such 
as rheumatology, the role of personalised medicine in PD needs to be increasingly considered. Personalised medicine for PD is not just a 
genetic approach to treatment but encompasses various strands of treatment. These include pharmacogenetic, pharmacological, as well as 
socio-demographic and lifestyle-related issues. Once these ‘enablers’ of personalised medicine are considered then satisfactory treatment 
for our patients with Parkinson’s can be achieved in an individualised manner. Future therapy for PD should move in that direction.
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Levodopa therapy and other dopamine replacement therapies (DRTs) have remained the 
cornerstone for the treatment of Parkinson’s disease (PD) since the 1960s.1 Many motor symptoms 
of PD can be partially reversed by DRT as well as more invasive therapies such as deep brain 
stimulation (DBS) of the subthalamic nucleus. However, many challenges remain both in the short 
and long term. Largely, these relate to the fact that the modern definition of PD has changed and 
the condition is now regarded as a complex disease with syndromic presentations manifesting 
as non-motor subtypes.2,3 Non-dopaminergic presentations, such as cholinergic, serotonergic 
and noradrenergic, can dominate the clinical phenotype of PD and form the basis of the recently 
described non-motor subtypes of PD.3–5 This heterogeneity of neuropathology and diversity 
of presentation needs treatment tailored to suit the clinical phenotypes. However, globally PD 
still continues to be treated by guideline-based algorithms underpinned by generic prescribing 
of levodopa and other DRTs. New drugs continue to be focussed on single targets when PD is 
known to be a multi-system, -neurotransmitter and -dysfunction-related disorder. Clearly, in future, 
this approach needs to change and the concept of a holistic personalised medicine strategy 
combining several strands of genetic, therapeutic, personal and socio-economic variables needs 
to be embraced.6,7
Personalised medicine
The concept of personalised medicine is subject to interpretation. The American Medical 
Association defines this ‘as each person’s unique clinical, genetic and environmental information’ 
while others consider personalised medicine purely from a genetic or pharmacogenetic ‘precision’ 
therapy standpoint.8 A more recent concept of the components that make up personalised 
medicine in PD as described recently by Titova and Chaudhuri is explained in Table 1.7
The concept of personalised medicine is particularly relevant for PD, a condition with multiple 
pathology and neurotransmitter-linked syndromes.2,3
For the development of new drugs relevant to the delivery of personalised medicine, robust 
animal models of PD are required. These models need to reflect the progressive pathology and 
multineurotransmitter defects that characterise PD. Such models based on toxin and/or genetic 
manipulation of rodents and primates remain elusive and represent an under-researched but key 
unmet need for the future of PD. Preliminary ‘bench’-based work has unravelled new potential targets 
for therapy which may help with aspects of non-motor symptoms (sleep dysfunction, cognition, pain 
and autonomic dysfunction) in PD, as well as some motor symptoms (gait freezing, dyskinesias). 
A combination of good animal model coupled with multiple non-dopaminergic target-based 
Editorial  Parkinson’s Disease
16 EUROPEAN NEUROLOGICAL REVIEW
treatment strategies may be the key to addressing the complex 
symptoms of PD. Neuroprotection, as well as neuromodulation, is 
currently an unmet need in PD. Whether such a bench-to-bedside 
translational approach (based on multiple non-dopaminergic targets) 
will have a role in neuroprotection or neuromodulation in PD remains 
to be seen.
The genomic aspect of personalised medicine involves the ability to 
identify ‘at-risk’ individuals based on known genetic susceptibility 
markers in the pre-prodromal stage of PD. Examples are heterozygote 
carriers of the glucocerebrosidase (GBA, GCase) gene, underlying 
Gaucher’s disease. This gene is responsible for approximately 5–10% of 
GBA mutations in PD patients.9 GBA mutation is now regarded as the most 
important genetic predisposing risk factor for PD and enhancing GCase 
activity or alteration of activity of chaperone proteins, such as HSP90 
(heat shock protein 90), may be beneficial.9 In this instance, personalised 
medicine will consist of a dual precision strategy of combining chaperone 
and GCase augmentation-based ‘cocktail’ therapy. Pharmacogenetics, 
on the other hand, will address inherited genetic differences in drug 
metabolic pathways which can influence individual clinical responses 
to drugs as well as adverse events.7,10 Using genetic markers, one may, in 
future, be able to predict the susceptibility of PD patients to side effects 
such as impulse control disorders or complications of levodopa therapy 
such as dyskinesia.
Other major factors involved in the delivery of personalised medicine 
include ageing and the concept of chronologic versus biologic age when 
increased life expectancy is taken into context. Therefore, it is possible 
that in the future, DBS of the subthalamic nucleus would be considered 
in ‘healthy aged’ PD patients even if they are older than 70 years. 
Currently, age remains a major limiting factor for offering DBS surgery 
to PD patients. Similarly, in younger patients depression and anxiety will 
have to be considered as such patients appear particularly susceptible 
to these non-motor sympotms.7 Non-motor and motor clinical subtypes 
of PD are an emerging and important clinical concept that will also 
determine treatment of PD.4–6 A cholinergic syndrome of PD would need 
a different treatment strategy to someone with a noradrenergic subtype 
of PD.2 Relevant clinical, imaging and genetic biomarkers may help 
define and drive these subtype-specific treatments. Other key issues are 
personality, lifestyle, body weight/body mass index, race and ethnicity as 
well as pharmacoeconomics.7 These are the ‘enablers’ of personalised 
medicine for future. Currently, our treatment strategies do not address 
these external but important variables that may determine the success 
of any therapy for PD. A ‘checklist’ of personalised medicine strategy 
supported by a strong multidisciplinary set-up should be the way forward 
to delivering successful treatment for PD in future. We need a combined 
holistic approach rather than a single target-focussed dopaminergic 
treatment strategy which has failed to deliver cure, neuroprotection, 
neuromodulation or effective treatment of non-motor symptoms of PD 
in the past 50 years. 
Table 1: Personalised medicine in Parkinson’s disease
Personalised 
Medicine Strategies
Pathways
Precision (genomic) 
medicine
Involves genomic principles such as clinical trial of gene 
therapy or HSP90 inhibitors for GBA positive/carriers at 
risk of developing PD.
Pharmacogenetic 
medicine
Involves monitoring and/or adjusting dopamine 
replacement therapies in PD based on genetic 
susceptibility to side effects (dyskinesias, psychosis, 
levodopa response, impulse control disorder).
Individualised 
medicine
Involves alteration or adjustment of therapeutic 
strategies based on racial differences/ethnicity, body 
weight, age.
Personality medicine Involves neuropsychologic input to delivery of 
personalised medicine driven by several strands of 
personality traits such as susceptibility to ICD, cognitive 
dysfunction, neuroticism, meta-cognitions, levodopa 
phobia.
Subtype-specific 
medicine
Involves modifications of therapeutic strategies based 
on clinically defined non-motor subtypes based on 
cholinergic, noradrenergic, serotonergic and mixed 
dysfunctions.
Lifestyle-specific 
medicine
Involves adjustment, modification as well as alterations 
of treatment based on lifestyle (work, environment of 
work, pharmacoeconomics, exercise).
Target-driven 
medicine
Involves drugs being developed for new non-
dopaminergic targets in PD. These include glucagon-like 
peptide 1 agonists, urate precursor agents or calcium 
channel antagonists as well as GABA, cannabinoid, 
purinergic and opioid target-driven drug developments.
GBA = glucocerebrosidase; HSP90 = heat shock protein 90; ICD = impulse control disorder; 
PD = Parkinson’s disease; Adapted from Titova N, Chaudhuri KR, Mov Disord, 2017.7
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